Ind-Swift Lab Peer Comparison

NSE: INDSWFTLAB | BSE: 532305

₹404.35

₹3.10 (0.77%)

As on 25-Sep-2026IST

Market cap

₹3,518 Cr

Revenue (TTM)

₹665 Cr

P/E Ratio

61.4

P/B Ratio

2.5

Div. Yield

0 %

Edit

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	3,518	36,902	28,103	16,761	15,213
Revenue (₹ Cr)	665	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	57.24	1,018.97	497.77	603.02	270.18
Net Margin (%)	7.95	10.47	20.72	22.63	23.29
RoE (%)	5.01	21.30	28.49	19.61	14.45
Price to Earnings	61.37	36.49	56.46	27.79	55.25
Price-To-Book	2.50	7.05	13.90	4.81	7.34

Income Statement (₹ Cr)

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	664.74	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	720.05	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	605.08	7,739.53	1,608.91	1,753.71	720.01
EBITDA	59.65	1,943.92	762.90	836.69	388.38
Depreciation	31.51	425.10	98.11	78.88	74.78
EBIT	28.14	1,518.82	664.79	757.81	313.60
Interest	0.96	148.45	26.33	5.43	0.26
Other Income	55.31	47.39	30.80	73.83	51.50
Exceptional Items	-11.24	-27.85	0.00	-25.66	-3.28
Profit before Tax	71.25	1,389.91	669.26	800.55	361.56
Provision for Tax	14.01	370.94	171.48	197.53	91.39
Profit after Tax	57.24	1,018.97	497.77	603.02	270.18

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	1,384.02	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	32.10	723.57	345.47	142.73	50.51
Current Liabilities	257.29	3,912.24	710.20	508.04	169.08
Total Liabilities	1,673.35	9,514.48	2,930.14	4,157.10	2,231.79

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	674.52	3,392.16	1,290.62	1,321.38	957.22
Current Assets	976.75	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	1,673.35	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	17.70	1,204.08	196.61	0.00	0.00
Net Current Assets	719.47	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	66.38	258.92	13.18	4.82	3.76

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-68.17	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-72.68	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	141.81	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	0.96	93.92	-56.08	-69.08	11.28

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	4.00	25.25	27.50	24.61	18.04
ROE (%)	5.01	21.30	28.49	19.61	14.45
ROA (%)	3.68	11.42	19.48	16.31	12.66
EBIT Margin (%)	4.23	15.68	28.03	29.25	28.29
Net Margin (%)	7.95	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	15.05	18.36	78.33	7.93	-6.72
EBIT Growth (%)	214.93	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	-75.11	32.39	182.61	21.66	-24.38
EPS Growth (%)	114.38	36.68	277.72	25.42	-21.99
Book Value Growth (%)	25.86	11.36	22.95	18.43	11.27

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	51.12	35.74	56.46	26.91	54.76
Price / Book Value	2.50	7.05	13.90	4.81	7.34
Dividend Yield (%)	0.00	0.19	0.16	0.37	0.52
EV/EBITDA	51.87	19.53	36.63	19.10	38.10
Market Cap (₹ Cr)	1,142.74	30,257.56	15,412.11	11,956.86	10,627.92

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.01	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.00	0.16	--	--	--
Current Ratio	3.80	1.43	2.09	5.21	7.39
Quick Ratio	3.22	0.82	1.37	3.85	5.46
Interest Coverage	75.30	10.36	26.41	148.49	1,386.30

	Ind-Swift Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	29.87	26.46	22.82	41.42	41.52
Asset Turnover	0.43	1.09	0.93	0.70	0.52
Receivable days	97.45	88.68	77.32	144.58	169.86
Inventory Days	70.35	84.11	80.83	96.67	97.92
Payable days	162.26	176.65	125.94	135.45	159.68
Cash Conversion Cycle	5.54	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.